Phase I Study of BVD-523 in Patients with Advanced Malignancies
What is the purpose of this trial?
To define the safety and tolerability of BVD-523 in patients with advanced malignancies by determining the dose-limiting toxicities (DLT), the maximum tolerated dose (MTD), and the recommended Phase 2 Dose (RP2D).
- 18 Years and older
- BioMed Valley Discoveries, Inc.
- Last Updated:
- Study HIC#: